David Barnes of Zeneca Group: Prescription for growth - The precocious, three-year-old U.K. drug company has outgrown its parent, doubled profits and won over onceskeptical investors. Its CEO tells how.
|Year of Publication:||
|Type of Publication:||Article|
|Title record from database:|| OLC-SSG Economic Sciences|
|Availability:||More access options|
|More options (other):|
|Description not available.|